CN Patent

CN119504738A — 作为mrgprx2拮抗剂的化合物及其制备方法和应用

Assigned to Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co · Expires 2025-02-25 · 1y expired

What this patent protects

本发明提供了一种式I所示化合物、其互变异构体、立体异构体、水合物、溶剂化物、药学上可接受的盐或前药；该化合物具有较好的MRGPRX2拮抗作用。

USPTO Abstract

本发明提供了一种式I所示化合物、其互变异构体、立体异构体、水合物、溶剂化物、药学上可接受的盐或前药；该化合物具有较好的MRGPRX2拮抗作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN119504738A
Jurisdiction
CN
Classification
—
Expires
2025-02-25
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Humanwell Innovative Drug Research and Development Center Ltd Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.